close before the end of this month. CHiL, which designs chips for power management in servers, PCs, and high-performance computing systems, has raised about $30 million since launching in 2006. International Rectifier, which has a manufacturing facility in Leominster, MA, said it will use the technology to help its customers focus on energy efficiency.
—Cambridge, MA-based NeuroPhage Pharmaceuticals, announced it had wrapped up $12.4 million in Series B financing led by Mérieux Développement. New investor Shire (NASDAQ: [[ticker:SHPGY]]), the Irish biopharma firm, also participated in the round for NeuroPhage, which is preparing its drug candidate for Alzheimer’s disease for Phase 1 clinical trials within the next two years.
–RXi Pharmaceuticals (NASDAQ: [[ticker:RXII]]), a Worcester, MA-based developer of RNA interference treatments, priced a public offering of common stock and warrants that is expected to gross $8.1 million. The proceeds of the offering, which is expected to close March 4, will be used for general corporate purposes.
—Cardiorobotics, a Raynham, MA-based developer of a robotic catheter for heart procedures, brought in $6.6 million out of an equity- and rights-based funding round that could total $12.5 million.
—Boston’s Sproxil, a company offering text message-based services for identifying counterfeit medication abroad, snapped up $1.8 million in funding from one investor, an SEC filing showed.
—Newton, MA-based Aircuity, a developer of a system for intelligently controlling air ventilation in commercial buildings, bumped up its most recent financing to $3.5 million out of a targeted $10 million equity round, an SEC filing showed. The firm reported last year that it raised $2.5 million from six investors; the new cash comes from one additional investor, according to the federal documents.
